CAS |
315-22-0 |
Chinese Name |
野百合碱 |
English Name |
Crotaline |
Synonym |
Monocrotaline |
Purity |
HPLC≥98% |
Molecular Formula |
C16H23NO6 |
Molecular Weight |
325.36 |
Appearance |
White to off-white solid |
Storage |
Powder : 2-8℃, 2 years; In solvent(mother liquid): -20℃, 1 month; -80℃, 6 months |
Solubility |
Soluble in DMSO≥10mg/ml |
MDL |
MFCD00084656 |
EC |
EINECS 628-506-2 |
InChIKey |
QVCMHGGNRFRMAD-XFGHUUIASA-N |
InChI |
InChI=1S/C16H23NO6/c1-9-13(18)23-11-5-7-17-6-4-10(12(11)17)8-22-14(19)16(3,21)15(9,2)20/h4,9,11-12,20-21H,5-8H2,1-3H3/t9-,11+,12+,15+,16-/m0/s1 |
PubChem CID |
9415 |
SMILES |
O=C(O[C@]1([H])CCN2[C@]1([H])C(CO3)=CC2)[C@H](C)[C@@](C)(O)[C@@](C)(O)C3=O |
Description |
It is a pyrrolizidine alkaloid, which has inhibitory effect on various tumors, and is considered to be an alkylating agent, which exerts anticancer activity through the alkylation of DNA. |
Target Point |
Others |
Passage |
Others |
Data Literature Source |
[1]. Gomez-Arroyo JG, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15; 302 (4) :L363-9.
[2]. Kusuma SS, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma. Anticancer Agents Med Chem. 2014; 14 (9) :1237-48.
[3]. Wilson DW, et, al. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol. 1992; 22 (5-6) :307-25.
[4]. Nogueira-Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm Pharmacol Ther. 2015 Dec; 35:8-16.
[5]. Rafikova O, et al. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed RatLung. PLoS One. 2016 Mar 3; 11 (3) :e0150480. |
Specification |
20mg 10mM*1mL in DMSO 100mg |